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Abstract 
Four structurally related Ru(II)-halide-PTA complexes, of general formula trans- or cis-
[Ru(PTA)4X2] (PTA = 1,3,5-triaza-7-phosphaadamantane, X = Cl (1, 2), Br (3, 4), were prepared 
and characterized. Whereas compounds 1 and 2 are known, the corresponding bromo derivatives 3 
and 4 are new. The Ru(III)-PTA compound trans-[RuCl4(PTAH)2]Cl (5, PTAH = PTA protonated 
at one N atom), structurally similar to the well-known Ru(III) anticancer drug candidates (Na)trans-
[RuCl4(ind)2] (NKP-1339, ind = indazole) and (Him)trans-[RuCl4(dmso-S)(im)] (NAMI-A, im = 
imidazole), was also prepared and similarly investigated. Notably, the presence of PTA confers to 
all complexes an appreciable solubility in aqueous solutions at physiological pH. The chemical 
behavior of compounds 1 – 5 in water and in physiological buffer, their interactions with two model 
proteins – cytochrome c and ribonuclease A – as well as with a single strand oligonucleotide (5'-
CGCGCG-3'), and their in vitro cytotoxicity against a human colon cancer cell line (HCT-116) and 
a myeloid leukemia (FLG 29.1) were investigated. Upon dissolution in the buffer, sequential halide 
replacement by water molecules was observed for complexes 1 – 4, with relatively slow kinetics, 
whereas the Ru(III) complex 5 is more inert. All tested compounds manifested moderate 
antiproliferative properties, the cis compounds 2 and 4 being slightly more active than the trans 
ones (1 and 3). Mass spectrometry experiments evidenced that all complexes exhibit a far higher 
reactivity toward the reference oligonucleotide than toward model proteins. The chemical and 
biological profiles of compounds 1 – 5 are compared to those of established ruthenium drug 
candidates in clinical development.  
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1. Introduction 
The interest in ruthenium derivatives – both coordination and organometallic compounds – as 
potential anticancer drugs has grown almost exponentially in the last 20 years and does not deserve 
much introduction [1-10].   
Since several years the cage-like monodentate phosphane 1,3,5-triaza-7-phosphaadamantane (PTA, 
Figure 1) has been widely used as a co-ligand in the design of organometallic Ru(II) anticancer 
compounds. The half-sandwich RAPTA-type compounds [RuCl2(η6-arene)(PTA)] (RAPTA = 
Ruthenium-Arene PTA, Figure 1) developed  by the group of Dyson are the most well-known [11-
17], but other Ru(II) compounds containing PTA have been investigated for their anticancer [18-23] 
or DNA-binding [24-26] properties.  
 
Figure 1. The PTA ligand (left) and a representative example of the RAPTA compounds (RAPTA-
T, right). 
PTA is an amphiphilic neutral ligand of moderate steric demand (cone angle 103°) that dissolves in 
several organic solvents and – most importantly – is characterized by a high solubility in water (ca. 
235 g/L) by virtue of H-bonding to the tertiary amine nitrogens [27,28]. It typically binds strongly 
to metal ions through the P atom in a monodentate fashion, imparting excellent water solubility to 
its complexes [27,28]. PTA has good σ- and pi-bonding abilities and, even though it has been 
defined as an air-stable, water-soluble version of PMe3 [29], spectroscopic and structural data 
suggest that it is closer to P(OMe)3 rather than PMe3 in terms of coordinating properties [27,28]. 
The solubility properties PTA-metal complexes were considered to be potentially very useful not 
only in homogeneous aqueous-organic biphasic catalysis [30-35], but also for the development of 
new metal anticancer drugs. In fact, in this context metal complexes containing PTA as co-ligand 
are anticipated to have good solubility in water for ease of in vitro investigation and in vivo 
administration, whereas maintaining sufficient lipophilicity to cross cell membranes and hence enter 
4 
 
cancer cells. In addition, at moderately acidic pH (the pKa of PTA is 5.89 [36]) one of the three N 
atoms of PTA is selectively protonated to generate PTAH. This feature was originally considered 
important for improving the selectivity of RAPTA compounds towards hypoxic cells of solid 
tumors that have slightly lower pH than normal cells (protonation of coordinated PTA inside the 
cell might lead to trapping the resulting cationic complex) [37]. However, this working hypothesis 
was later abandoned, since the pKa of PTA typically drops to ca. 3 when bound to ruthenium 
[21,38], thus well below the pH of cancer cells. Finally, PTA appears to be a quite safe molecule in 
terms of toxicity. 
Given these premises, we were surprised at realizing that even though PTA has been extensively 
used as co-ligand in many Ru half-sandwich anticancer compounds, no investigation has been yet 
performed on the ruthenium-halide complexes of PTA, i.e. on complexes in which PTA is the main 
ligand. 
Two neutral chloro Ru(II)-PTA isomers, namely trans-[RuCl2(PTA)4] (1) and cis-[RuCl2(PTA)4] 
(2) are known since several years and can be obtained in good yield upon treatment of hydrated 
RuCl3 with excess PTA [39-42]. In this work we report the preparation and characterization of the 
corresponding – and new – bromo derivatives, trans-[RuBr2(PTA)4] (3) and cis-[RuBr2(PTA)4] (4), 
and of the Ru(III) complex trans-[RuCl4(PTAH)2]Cl (5), structurally similar to well-known Ru(III) 
anticancer drug candidates (Na)trans-[RuCl4(ind)2] (NKP-1339, ind = indazole) and (Him)trans-
[RuCl4(dmso-S)(im)] (NAMI-A, im = imidazole) [1-10]. The chemical behavior of compounds 1 – 
5 in water and in physiological buffer, their interactions with two model proteins – cytochrome c 
(cyt c) and ribonuclease A (RNase A) – as well as with a single strand reference oligonucleotide (5'-
CGCGCG-3', ODN4), and their in vitro cytotoxicity against a human colon cancer cell line (HCT-
116) and a myeloid leukemia (FLG 29.1) are also reported. 
2. Experimental procedures 
2.1 Materials and methods 
All chemicals were purchased from Sigma-Aldrich and used as received. Solvents were of reagent 
grade. The compounds trans-[RuCl2(PTA)4] (1), cis-[RuCl2(PTA)4] (2), and [(dmso)2H]trans-
[RuCl4(dmso-S)2] were prepared as described in the literature [39-43]. Hydrated RuCl3 was a gift 
from BASF Italia Srl, whereas hydrated RuBr3 was purchased from Strem Chemicals.  
Horse heart cytochrome c (cyt c) (C7752), Ribonuclease A (RNase A) from bovine pancreas type 
XII-A (RNase 055K7695), as well as all the chemicals for the various buffer solutions were 
purchased from Sigma. Single strand oligonucleotide ODN4 (5'-CGCGCG-3') was purchased from 
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Jena Bioscence (Oligo4_4, 5073). All the chemicals and proteins were used as received without 
further purification, and the solutions were prepared with deionized water produced by a Millipore 
system. 
Mono- (1H (400 or 500 MHz), 13C (125.7 MHz), 31P (161 or 202 MHz)) and bi-dimensional (1H-1H 
COSY and 1H-13C HSQC) NMR spectra were recorded at room temperature on a JEOL Eclipse 
400FT or on a Varian 500 spectrometer. 1H and 13C chemical shifts were referenced to the peak of 
residual non-deuterated solvent (δ = 7.26 and 77.16 for CDCl3) or were measured relative to the 
internal standard DSS (δ = 0.00) for D2O. 31P chemical shifts were measured relative to external 
85% H3PO4 at 0.00 ppm. ESI mass spectrometry measurements were performed on a Perkin-Elmer 
APII spectrometer  on an Orbitrap high-resolution mass spectrometer (Thermo Scientific, San Jose, 
CA, USA) equipped with a conventional ESI source. UV-vis spectra were obtained on an Agilent 
Cary 60 spectrophotometer, using 1.0 cm path-length quartz cuvettes (3.0 mL). Elemental analyses 
were performed in the analytical laboratories of the Department of Chemistry of the University of 
Bologna. A home-made LED apparatus was used for performing the photochemical reactions. 
Briefly, it consists of a plastic-coated cylindric well capable of hosting an NMR tube or a test-tube 
(Ø = 20 mm, h = 110 mm). The inside of the apparatus is lined with four pairs of LED stripes, each 
containing five LEDs of the same color that emit in a narrow spectral range (ca. 10 nm). LED 
stripes of the same color are located opposite to each other. One or more colors can be activated at 
the same time, and the LED emission power can be regulated from 1 to 40 mW. The blue LEDs (λ 
= 470 nm) were used in this case.  
 
2.2 Synthesis and characterization of ruthenium compounds 
trans-[RuBr2(PTA)4] (3). RuBr3·3H2O (60.0 mg, 0.15 mmol) was partially dissolved in 7 mL of 
ethanol. A slight excess of PTA (96.55 mg, 0.615 mmol) was added and the mixture was refluxed 
for 3 h. A clear solution was obtained within 1 h from which a dark red solid began to form. It was 
eventually removed by filtration and washed with ethanol. The solid was treated on the filter with 
chloroform (ca. 10 mL) to obtain an orange solution. A small amount of grey solid that remained 
undissolved on the filter was discarded. The solvent was completely removed by rotary evaporation, 
affording pure 3, according to 1H and 31P NMR spectra (Yield: 93.9 mg, 68%). X-ray quality 
crystals of 3 were obtained by slow diffusion of diethyl ether into a chloroform solution of the 
complex. Elemental analysis for the raw material: calcd for [C24H48N12Br2P4Ru·5H2O] (MW: 
979.48): C, 29.43; H, 5.97; N, 17.16. Found: C, 29.57; H, 6.10; N, 17.09. 1H NMR (D2O), δ (ppm): 
4.61 (br s, 24H, NCH2N), 4.40 (br s, 24H, NCH2P). 13C NMR from the HSQC spectrum (D2O), δ 
(ppm): 70.5 (NCH2N), 51.9 (NCH2P). 31P-NMR (D2O), δ (ppm): –54.5 (s). 1H NMR (CDCl3), δ 
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(ppm): 4.60, 4.55 (ABq 24H, NCH2N, JAB 13.2 Hz), 4.46 (br s, 24H, NCH2P). 13C NMR from the 
HSQC spectrum (CDCl3), δ (ppm): 73.5 (NCH2N), 54.0 (NCH2P). 31P NMR (CDCl3), δ (ppm): –
56.5 (s). ESI mass spectrum (m/z): 811.12 (M – Br)+, calcd 811.129; 733.97 (M – PTA + H+)+, 
calcd 733.32. 
cis-[RuBr2(PTA)4] (4). trans-RuBr2(PTA)4 (50.0 mg, 0.056 mmol) was dissolved in 5 mL of water 
and irradiated with blue light (λ = 470 nm, 40 mW) for 2.30 h. The orange solution turned to yellow 
within 1 h. Complete removal of the solvent by rotary evaporation afforded pure 4, according to 1H 
and 31P NMR spectra, as a yellow solid (Yield: 48.0 mg, 96%). X-ray quality crystals of 4 were 
obtained by slow diffusion of acetone into a water solution of the complex. Elemental analysis calcd 
for [C24H48N12Br2P4Ru·5H2O] (MW: 979.48): C, 29.43; H, 5.97; N, 17.16. Found: C, 29.55; H, 6.11; 
N, 17.07.1H NMR (D2O + exc. NaBr, see text), δ (ppm): 4.70 (m, 24H, NCH2N), 4.56 (br s, 12H, 
NCH2P), 4.23 (br s, 12H, NCH2P). 31P NMR (D2O + exc. NaBr, see text), δ (ppm): –24.1 (t, 2P, 2JP-
P = 28.2 Hz, PTA trans to Br), –64.7 (t, 2P, 2JP-P = 28.2 Hz, mutually trans PTAs). 1H NMR 
(CDCl3), δ (ppm): 4.54 (br s, 12H, NCH2P), 4.50 (m, 24H, NCH2N), 4.12 (br s, 12H, NCH2P). 13C 
NMR from the HSQC spectrum (CDCl3), δ (ppm): 73.0 (NCH2N), 59.2 (NCH2P), 55.4 (NCH2P). 
31P NMR (CDCl3), δ (ppm): –27.0 (t, 2P, 2JP-P = 27.4 Hz , PTA trans to Br), –67.3 (t, 2P, 2JP-P = 
27.4 Hz, mutually trans PTAs). ESI mass spectrum (m/z): 811.12 (M – Br)+, calcd 811.129. 
trans-[RuCl4(PTAH)2]Cl (5). [(dmso)2H]trans-[RuCl4(dmso-S)2] (150.0 mg, 0.27 mmol) [43] was 
dissolved in 15 mL of methanol, obtaining an orange solution. 0.500 µL of 37% aqueous HCl and 
two equivalents of PTA (84.8 mg, 0.54 mmol) were added; a brown solid began to precipitate 
immediately. The mixture was stirred for 1 h and then the solid was collected by filtration, washed 
with methanol and diethyl ether and dried in vacuo. The solid was dissolved in 4.5 mL of water at 
reflux. Abundant small crystals of 5, suitable for X-ray diffraction, were obtained upon allowing the 
solution to cool down to room temperature. The crystals were filtered, washed with a small amount 
of water and dried in vacuo (yield: 115.8 mg, 72%). Elemental analysis calcd for 
[C12H26N6Cl5P2Ru·2H2O] (MW: 630.67): C 22.85; H 4.79; N 13.33. Found: C 23.36; H 4.51; N 
13.05 1H NMR (D2O), δ (ppm): 0.37 (br s, 12H), –1.17 (br s, 12H). ESI mass spectrum: 400.7 m/z 
(M – PTA)–, calcd 400.0. 
 
2.3 X-ray diffraction  
Data collections were performed at the X-ray diffraction beamline (XRD1) of the Elettra 
Synchrotron of Trieste (Italy), with a Pilatus 2M image plate detector. Complete datasets were 
collected at 100 K (295 K for compound 5, since the crystals cracked at low temperature) with a 
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monochromatic wavelength of 0.700 Å through the rotating crystal method. The crystals were 
dipped in paratone-N and mounted on the goniometer head with a nylon loop. The diffraction data 
were indexed, integrated and scaled using XDS [44]. The structures were solved by direct methods 
using SIR2014 [45], Fourier analyzed and refined by the full-matrix least-squares methods based on 
F2 implemented in SHELXL-2014 [46]. The Coot program was used for modeling [47]. Anisotropic 
thermal motion modeling was then applied to all atoms. Hydrogen atoms were included at 
calculated positions with an isotropic temperature factor equal to 1.2 (1.5 for disordered water 
molecules) times the equivalent isotropic temperature factor of the atom to which they were 
bonded. CCDC-1429123 (3), 1429111 (4), 1429110 (5). Essential crystal and refinement data, 
together with selected bond distances and angles, are reported in the SI. 
2.4 Spectrophotometric studies 
To assess the stability of the compounds in physiological like conditions, spectrophotometric 
studies were performed by a Varian Cary 50 Bio UV–vis spectrophotometer. Freshly prepared 
concentrated solutions (10–2 M for compounds 1–4, 10–4 M for compound 5) of each compound 
dissolved in milliQ water were diluted in phosphate buffer (PB, 10 mM phosphate, pH 7.4). The 
concentration of each compound in the final sample was 3×10−5 M. The resulting solutions were 
monitored by collection of the electronic spectra for 24 h at room temperature. 
2.5 Interactions with biomolecules 
Ruthenium complex–protein/oligonucleotide adducts were prepared starting from a solution of each 
model protein at a concentration of 10–4 M in 20 mM ammonium acetate buffer, pH 7.4, or from a 
10–4 M solution of ODN4 in milliQ water. Then, the ruthenium complex was added (3:1 metal-to-
protein/oligonucleotide ratio) to the solution and the mixture was incubated at 37 °C for 24 h, using 
Thermoblock (Falc, TD15093). Protein samples were analyzed after a 20-fold dilution with milliQ 
water (the final concentration of the protein was 5 µM), while ODN4 samples were diluted with a 
mixture of 50% milliQ water and 50% MeOH to a final concentration of 10 µM. ESI-MS spectra 
were recorded by direct introduction of the sample at a flow rate of 5 µL/min into an Orbitrap high-
resolution mass spectrometer (Thermo Scientific, San Jose, CA, USA) equipped with a 
conventional ESI source. The working conditions for ruthenium complex-protein adducts were as 
follows: spray voltage 3.1 kV, capillary voltage 45 V and capillary temperature 220 °C. The sheath 
and the auxiliary gasses were set at 17 (arbitrary units) and 1 (arbitrary unit), respectively. For 
acquisition, Xcalibur 2.0 (Thermo Scientific) was used and monoisotopic and average deconvoluted 
masses were obtained by using the integrated Xtract tool. For spectrum acquisition, a nominal 
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resolution (at m/z 400) of 100,000 was used. ESI-MS spectra of the ruthenium complex-ODN 
adducts were recorded in negative ion mode. The working conditions were as follows: spray voltage 
4.5 kV, capillary voltage –10 V and capillary temperature 270 °C. The sheath gas was set at 10 
(arbitrary units) whereas auxiliary gas was kept at 5 (arbitrary units). 
 
2.5 Cellular studies 
Cell cultures. HCT-116 (human colon cancer) and FLG 29.1 (human myeloid leukemia) cell lines 
were maintained in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% bovine calf 
serum (HyClone) and maintained at 37°C in a humidified atmosphere in 5% CO2 in air.  
Pharmacology experiments. Cells were seeded in a 96-well flat-bottomed plate (Corning-Costar, 
Corning, NY, USA) at a cell density of 104 cells per well in RPMI complete medium. Each 
ruthenium compound was added at final concentrations of 200 µM, 100 µM, 50 µM, 10 µM, and 2 
µM. After 24 h, viable cells (determined by Trypan blue exclusion) were counted in triplicate using 
a haemocytometer. Each experimental point represents the mean of four samples carried out in three 
separate experiments.  
Trypan blue assay. Cells viability was assessed by the Trypan blue exclusion assay. In brief, 10 µl 
of 0.4% trypan blue solution was added to 10 µl cell suspension in culture medium. The suspension 
was gently mixed and transferred to a haemocytometer. Viable and dead cells were identified and 
counted under a light microscope. Blue cells failing to exclude dyes were considered nonviable, and 
transparent cells were considered viable. The percentage of viable cells was calculated on the basis 
of the total number of cells (viable plus nonviable). The IC50 value (i.e. the dose that caused 
apoptosis of 50% of cells) was calculated by fitting the data points (after 24 h of incubation) with a 
sigmoidal curve using Calcusyn software (Biosoft). 
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3. Results and Discussion 
The present study is focused on four structurally related Ru(II)-PTA complexes of general formula 
trans- or cis-[Ru(PTA)4X2] (PTA = 1,3,5-triaza-7-phosphaadamantane, X = Cl (1, 2), Br (3, 4)), and 
on the Ru(III)-PTA compound trans-[RuCl4(PTAH)2]Cl (5, PTAH = PTA protonated at one N 
atom). Their structures are synoptically represented in Figure 2.  
 
Figure 2. Schematic structures of compounds 1 – 5. 
 
3.1 Synthesis and chemical characterization 
The preparation of the new bromo derivatives trans-[RuBr2(PTA)4] (3) and cis-[RuBr2(PTA)4] (4) 
was performed following a procedure very similar to that reported in the literature for the 
corresponding chloro isomers 1 and 2, respectively [39-42], using hydrated RuBr3 rather than RuCl3 
as starting material. In summary, treatment of RuBr3·3H2O with excess PTA in refluxing ethanol 
afforded in high yield trans-[RuBr2(PTA)4] (3), that precipitates spontaneously. This kinetic 
product was quantitatively transformed into the thermodynamically stable cis isomer cis-
[RuBr2(PTA)4] (4) by irradiating an aqueous solution with blue light (λ = 470 nm) for 2.5 h.  
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Figure 3. Molecular structures (50% probability ellipsoids) of trans-[RuBr2(PTA)4]·0.682(C4H10O) 
(3, left) and cis-[RuBr2(PTA)4]·0.37(H2O) (4, right). The crystallization water molecule with minor 
occupancy factor in the structure of 3 has been omitted for clarity. Color code for unlabeled atoms: 
N = blue, O = red. 
The molecular structures of 3 and 4 (Figure 3) are closely comparable with those of the 
corresponding dichloro derivatives [39-41]. To begin with, they show distortions from the perfect 
octahedral geometry around Ru(II) very similar to those found in 1 and 2. In complex 3 the two 
pairs of trans PTA ligands are vertically displaced in opposite directions from the average 
equatorial plane (163.46(2) and 164.05(2)°). In complex 4 the two trans PTA ligands make a P–
Ru–P angle of 164.639(18)° (164.8(1)° in 2) and are bent towards the Br atoms. A similar bending 
is found for the two cis PTA's (97.067(19)° vs 96.5(1)° in 2). Thus, in both isomers the PTA 
moieties move towards the less sterically encumbered region occupied by the two Br ligands. The 
two trans Ru–Br distances in 3 are nearly equal (2.5695(4) and 2.5582(4) Å) and slightly shorter 
than those found in the cis isomer 4 (2.6142(14) and 2.6289(4) Å), consistent with the stronger 
trans influence of PTA. Similarly, the Ru–P distances in the trans isomer range between 2.3253(7) 
and 2.3484(7) Å (cfr 2.316(2) – 2.353(2) Å in 1), whereas in 4 the two Ru–P distances trans to Br 
are considerably shorter (2.2805(13) and 2.2655(5) Å; cfr 2.260(2) Å trans to Cl in 2) than those of 
the two trans PTA’s (2.4001(5) and 2.3562(5) Å; cfr 2.370(2) Å in 2), which – in turn – are close to 
(but slightly longer than) those in the trans isomer.  
The 1H and 31P NMR features of 3 and 4 and their chemical behavior in aqueous solution are also 
similar to those of the corresponding chloro compounds [39-42]. Whereas a light-protected D2O 
solution of 3 is perfectly stable for days at room temperature according to NMR spectroscopy, the 
cis isomer 4 immediately equilibrates with the aqua species cis-[RuBr(OH2)(PTA)4]+ and cis-
[Ru(OH2)2(PTA)4]2+. Pure 4 – according to the 31P NMR spectrum – was obtained only upon 
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addition of a large excess NaBr to the D2O solution. This geometry-dependent behavior is in 
accordance with the trans influence of PTA observed in the X-ray structures. Consistent with 
literature data on Ru(II)-halide complexes, the bromide ligands proved to be more easily released 
than the chlorides [48]. An equilibrium constant of 2.42×10-2 M was measured between 4 and its 
mono-aqua derivative cis-[RuBr(OH2)(PTA)4]+ by integration of the 31P NMR signals (to be 
compared with 1.39×10-2 M for complex 2). The measurement was performed in the presence of the 
minimum amount of NaBr sufficient to inhibit the formation of cis-[Ru(OH2)2(PTA)4]2+. The 
electronic absorption spectra of 1 and 3 in chloroform (SI) show a single band of low intensity in 
the visible region (λmax = 452 nm for 1 and 475 nm for 3), whereas those of the less symmetric cis 
isomers (SI) are characterized by a broad band, probably the overlap of two bands, at higher 
frequencies (λmax = 348 nm for 2 and 368 nm for 4). They are attributed to MLCT transitions from 
Ru(II) to the pi-acceptor PTA, as in the corresponding Ru(II)–CH3CN [48] and Ru(II)–dmso [49] 
compounds. Consistent with this assignment, the main absorption band of each Br isomer is red-
shifted of ca. 20 nm compared to that of the corresponding Cl species (bromide, being a better pi-
donor than chloride, leads to an increase in the energy of the t2g orbitals) [48]. The electronic 
absorption spectra of 2 and 4 in pure water and after addition of excess NaCl or NaBr are consistent 
with the NMR findings in D2O (SI; see below the results in phosphate buffer).  
The Ru(III) complex trans-[RuCl4(PTAH)2]Cl (5) had been previously identified in very low yield 
upon recrystallization of 1 (to which a cis geometry had been wrongly assigned) in an aqueous HCl 
solution (the main product being the bis-protonated Ru(II) species cis-[RuCl2(PTA)2(PTAH)2]Cl2) 
[40]. Its origin – either a side product in the preparation of 1 due to incomplete Ru(III) reduction, or 
originated by adventitious air oxidation of 1 during the prolonged crystal growing experiments – 
was unclear. Even though neglected after the original report, we found complex 5 particularly 
exciting since it is structurally similar to the two best known Ru(III) anticancer drug candidates, 
namely NAMI-A and NKP-1339 (Figure 4) [1-10].  
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Figure 4. Comparison of the structurally related anions of the Ru(III) complexes NAMI-A (left), 
NKP-1339 (center) and 5 (represented in its anionic form with unprotonated PTA). 
Interestingly, compound 5, depending on the degree of protonation of the PTA ligands, can be 
cationic (trans-[RuCl4(PTAH)2]+), neutral (trans-[RuCl4(PTA)(PTAH)]), or anionic (trans-
[RuCl4(PTA)2]–). We found that 5 can be obtained in high yield upon treatment of the Ru(III)-dmso 
precursor [(dmso)2H]trans-[RuCl4(dmso-S)2] [43] with PTA in MeOH/HCl mixtures (Scheme 1). 
Due to the acidic conditions used in the preparation, both PTA ligands undergo protonation and the 
complex precipitates spontaneously in almost quantitative yield in its cationic form. 
 
Scheme 1. Selective preparation of trans-[RuCl4(PTAH)2]Cl (5) from the Ru(III)-dmso precursor 
[(dmso)2H]trans-[RuCl4(dmso-S)2]. 
Dark crystals of trans-[RuCl4(PTAH)2]Cl·H2O (5·H2O) suitable for X-ray structure determination 
were obtained upon recrystallization of the raw product from water.  
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Figure 5. Molecular structure (50% probability ellipsoids) of trans-[RuCl4(PTAH)2]Cl·H2O 
(5·H2O). Only the chloride in the position of maximum occupancy is shown. Color code for 
unlabeled atoms: N = blue, O = red. 
The molecular structure of complex 5 is in close agreement with that already published for this 
species [40]. One N atom in each PTA ligand is fully protonated, as confirmed by lengthening of 
the corresponding C–N bonds from 1.456(4) Å to 1.516(4) Å in the protonated form [27,28,38]. 
The positive charge of the complex is balanced by an external chloride ion that is disordered over 
three different positions. 
The 1H NMR spectrum of 5 in D2O consists of two relatively broad peaks for bound PTA (one for 
the PCH2N and the other for the NCH2N protons) shifted upfield with respect to the typical PTA 
region (δ = 0.37 and –1.17 ppm, no assignment could be made). Consistent with the fact that P of 
PTA is directly bound to the paramagnetic Ru(III) nucleus, we were unable to observe any 
resonance in the 31P NMR spectrum (most likely the expected singlet is too broad to be detected). 
The visible region of the absorption spectrum of 5 in water shows the typical halide-to-Ru(III) 
charge-transfer manifold typical of all Ru(III) complexes with a similar structure [43,48-50]: a main 
broad band centered at 383 nm and a weaker band at 444 nm (SI). The spectrum shows a very slow 
decrease of the band intensities (ca. –15 % in 72h at room temperature) without significant shifts in 
the absorption maxima (SI). Such spectral changes are not consistent with slow chloride release 
[43,48-50] (in fact, addition of excess NaCl after 72h induces no significant change in the 
spectrum), but rather suggest a progressive aggregation (and consequent decrease of the complex 
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concentration), perhaps involving species with different charge derived from the deprotonation 
equilibria of coordinated PTAH. 
 
3.2 Spectrophotometric analysis. 
The studied compounds display a remarkable solubility and a sufficient stability in water, thus 
being well amenable for biological studies. UV-vis absorption spectroscopy was chosen as the 
election method to monitor the behavior of the five complexes in a reference buffer at physiological 
pH over a time period of 24h. Time dependent spectral profiles for each compound are reported in 
Figure 6 (1-4) and Figure 7 (5).  
 
Figure 6. Time course UV-vis spectra of compounds 1 (A), 2 (B), 3 (C), and 4 (D) dissolved in 10 
mM phosphate buffer, pH 7.4, over 1 hour. Figures show spectra recorded at t = 0 (black solid line), 
10 min (red dashed line), 30 min (blue dotted line), and 1h (green dashed-dot line). (For 
interpretation of the references to color in this figure, the reader is referred to the web version of 
this article.) 
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Figure 7. Time course UV-vis spectra of compound 5 dissolved in 10 mM phosphate buffer, pH 
7.4, over 24 hours. Figures show spectra recorded at t = 0 (black solid line),1h (red dashed line), 6h 
(blue dotted line), 12h (green dashed-dot line), and 24h (brown dashed-dot-dot line). (For 
interpretation of the references to color in this figure, the reader is referred to the web version of 
this article.) 
 
For the trans isomers 1 and 3, contrary to what was observed by NMR spectroscopy in D2O, where 
they are stable, spectral changes occurred within one hour (SI): for each complex the absorption 
band in the visible region (456 nm for 1 and 475 nm for 3) progressively disappeared, whereas the 
band in the near UV region shifted to lower frequencies (325 nm for 1 and 344 nm for 3). These 
spectral changes are ascribed to the progressive release of the halide ligands, even though 
concomitant partial release of PTA cannot be excluded. Conversely, the cis isomers 2 and 4 
displayed a different behavior, similar to that found in pure water (SI): upon dissolution in the 
buffer both complexes showed a similar spectrum, with a band at 340 nm, whereas in chloroform 
solution compound 4 has a band which is red-shifted of ca. 20 nm compared to that of compound 2 
(see above). In addition, the spectra in phosphate buffer showed no significant change with time, 
consistent with the NMR findings (in D2O) that evidenced rapid equilibration of the cis isomers 
with the mono- and diaqua species upon release of the halide ligands. The aquation process, that is 
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expected to be more pronounced at the concentration used in the UV-vis spectra (compared to 
NMR), apparently leads to the common cis-[Ru(OH2)2(PTA)4]2+ species.  
The spectrum of compound 5 changed with time in a manner similar (but faster) to that observed in 
pure water (see above)  (Figure 7). 
 
3.3 Reactions with model proteins.  
The interactions of compounds 1-5 with the model proteins RNase and cyt c were subsequently 
monitored by ESI-MS analysis. Results are summarized in Figure 8 (interaction with cyt c) and in 
the SI (with RNase A). In general, as can be judged from the amount of the metallodrug-protein 
adducts that are formed, the reactivity is very limited, in particular with compound 5. Nevertheless, 
careful analysis of ESI mass spectra allowed us to identify the metallic fragments that are bound to 
the proteins. In most cases mono-metalated derivatives are formed, in which the metallic fragment 
consists of the ruthenium center plus a variable number of PTA ligands. In particular, Figure 8 
shows that in the case of cyt c the main peaks can be assigned to adducts bearing the fragments 
[Ru(PTA)]2+, [Ru(PTA)2]2+ and [Ru(PTA)3]2+, respectively. In some cases fragments containing Cl– 
or Br– were also detected: [RuCl(PTA)2]+ for compound 1, [RuBr(PTA)4]+ for compound 3, 
[RuBr(PTA)3]+ for compound 4, [RuCl3(PTAH)]+ and [RuCl4(PTAH)2]+ for compound 5. The 
interactions with RNase A (SI) lead to adducts that are similar to those obtained with cyt c. 
Moreover, adducts with [RuCl]+ (for compounds 1 and 2) and [RuBr]+ (for compound 3 and 4) 
were also detected.   
Overall, the interactions detected between the model proteins and the five ruthenium complexes are   
rather modest, suggesting that proteins might not be primary and/or relevant targets. 
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A B C
D E
Figure. 8. LTQ Orbitrap ESI mass spectra of compound 1 (A), 2 (B), 3 (C), 4 (D) and 5 (E) 
dissolved in 20 mM ammonium acetate buffer, pH 7.4, in the presence of cyt c after 24h incubation 
at 37°C. The spectra in the back are the amplification of a region of the front spectra. 
 
3.4 Reactions with a single strand oligonucleotide 
The lack of relevant adduct formation with the selected model proteins, together with the evidence 
in literature that several Pt and Ru-based complexes may exert their biological effects through a 
direct interaction with DNA [51-53], prompted us to study the reactivity of the five ruthenium 
complexes with a DNA model system.  
Investigations were performed on a single strand oligonucleotide, ODN4, (5'-CGCGCG-3'), chosen 
as reference, and the interactions were monitored through ESI-MS. In this case adduct formation 
was far more evident than with model proteins, with the exception of compound 5 (Figure 9). 
Adducts between the oligonucleotide and ruthenium fragments containing more than one PTA 
ligand were identified. Specifically, the main adduct between ODN4 and the trans isomers 1 and 3 
(Figure 9A and C) contains the fragment [Ru(PTA)2]2+, whereas that with the  cis isomers 2 and 4 
(Figure 9B and D) bears [Ru(PTA)3]2+. Notably, even though compound 2 was reacted with ODN4 
under the same conditions as the other ruthenium complexes, a drastic decay in the intensity of ESI- 
MS peaks was detected in this case, which might be tentatively ascribed to the occurrence of 
aggregation/precipitation processes. Nonetheless, a low intensity spectrum could be obtained 
(Figure 9B) and peak assignment was performed. It is worth mentioning that in this case the peak 
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relative to the free oligonucleotide was not detected after 24h incubation at 37°C, revealing that all 
the ODN4 has reacted. The only adduct that could be identified was that with the metallic fragment 
[Ru(PTA)3]2+.  
In addition to the main adduct, ESI mass spectra of compounds 1 and 3 show peaks corresponding 
to derivatives: 2[Ru(PTA)2]2+ and [Ru(PTA)2]2++[RuCl(PTA)3]+ for compound 1, 
[Ru(PTA)2]2++[RuBr(PTA)3]+ and 2[RuBr(PTA)3]+ for compound 3. In the case of compound 4, 
other mono- and bis-metalated adducts were also detected (i.e.  [Ru(PTA)4]2+ and 2[RuBr(PTA)3]+).  
The interaction between more inert compound 5 and ODN4 is less evident and only small amounts 
of adducts could be detected. In fact, Figure 9E shows two peaks corresponding to the adducts 
between ODN4 and the fragments [Ru(PTA)]3+ and [Ru(PTA)2]3+, while most of the free compound 
in solution is in the form [RuCl4(PTA)]- or [RuCl4(PTA)2]- (SI). 
It is evident that, in agreement with the NMR and UV-vis findings reported above, the two cis 
complexes (2 and 4) are more reactive than the respective trans species (1 and 3), and that the 
adduct formation is more evident with the chloride than with the bromide. 
A B C
D E
Figure 9. LTQ Orbitrap ESI mass spectra of compound 1 (A), 2 (B), 3 (C), 4 (D) and 5 (E) 
dissolved in milliQ water, in the presence of ODN4 after 24h incubation at 37°C.   
 
3.5 Antiproliferative properties 
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The antiproliferative properties of compounds 1-5 were assessed against two cell lines: HCT-116 
(human colon cancer) and FLG 29.1 (human acute myeloid leukemia) according to the method 
described in the experimental section. Both cell lines were treated for 24 hours with increasing 
concentrations of the drug and IC50 values determined (calculated through the Trypan blue 
exclusion test). The findings are summarized in Table 1. In general, the antiproliferative effects are 
quite moderate, yet the two cis isomers 2 and 4  were found to be significantly more effective than 
the trans congeners 1 and 3 in the leukemia cell line, whereas the cytotoxicity of compound 5 is far 
lower. It is also remarkable that the cytotoxic profile of 1 is virtually identical to that of 3, and the 
same similarity was found for the two cis isomers 2 and 4. This finding suggests that – in both cases 
– similar halide-free species are ultimately responsible for the biological effects. Such species are 
presumably different for the two stereoisomers because the activity clearly depends on the geometry 
of the complex. These results, together with the reactivity profiles toward the oligonucleotide, point 
out that the biological effects may be related to the direct interaction of these ruthenium compounds 
with DNA. 
Table 1. IC50 values (µM) for compounds 1-5, in comparison with cisplatin, on a solid tumor cell 
line, HCT 116, and a myeloid leukemia cell lines, FLG 29.1. 
Compound FLG 29.1 HCT 116 
trans-RuCl2(PTA)4 (1) >200 >100 
cis-RuCl2(PTA)4 (2) 60.83 ± 0.59 >100 
trans-RuBr2(PTA)4 (3) >200 >100 
cis-RuBr2(PTA)4 (4) 59.33 ± 0.41 >100 
trans-[RuCl4(PTAH)2]Cl·2H2O (5) 84.91 ± 0.39 >100 
Cisplatin 24.33 ± 0.75a 7.65 ± 0.63b  
a
 From ref. 54. b From ref. 55. 
 
4. Conclusions 
The cage-like monodentate phosphine 1,3,5-triaza-7-phosphaadamantane (PTA) has been 
extensively used as co-ligand in many Ru half-sandwich anticancer compounds [11-26], where it 
plays a central role in increasing the aqueous solubility and in affecting the solution  behavior 
[27,28]. However, no biological investigation has been yet performed on ruthenium complexes in 
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which PTA is the main ligand. With the aim of filling this gap, in this work we reported the 
preparation and characterization for prospective biomedical applications of a group of five 
ruthenium-PTA-halide compounds: the four structurally related Ru(II) complexes of general 
formula trans- or cis-[Ru(PTA)4X2], X = Cl (1, 2), Br (3, 4)), and the Ru(III) compound trans-
[RuCl4(PTAH)2]Cl (5, PTAH = PTA protonated at one N atom).   
The chemical behavior of the Ru(II) compounds in aqueous solution was found to depend on their 
structure and on the pH.  In pure water, whereas the trans isomers 1 and 3 are very stable (in the 
dark), the cis analogues 2 and 4 readily equilibrate with the aqua species cis-[RuX(OH2)(PTA)4]+ 
and cis-[Ru(OH2)2(PTA)4]2+.  However, when dissolved in phosphate buffer at physiological pH, 
also the trans isomers undergo aquation processes that can be mainly ascribed to halide 
replacement. The reactivity of the four compounds with two model proteins, cytochrome c (cyt c) 
and ribonuclease A (RNase A), and with a DNA single strand reference oligonucleotide, ODN4 (5'-
CGCGCG-3'), was investigated by mass spectrometry and their in vitro cytotoxicities against two 
representative cancer cell lines were also assessed. In general, compounds 1 - 4 showed a pairwise 
different – structure-related – behavior, clearly indicating that the four isomers do not converge to a 
common species but rather to two main halide-free stereoisomeric Ru-PTA fragments. Their 
reactivity towards cyt c and RNase A was found to be quite limited and minimal amounts of protein 
adducts were formed. Compounds 1 – 4 exhibited a far higher reactivity toward the reference 
oligonucleotide than toward model proteins and substantial amounts of adducts – mainly mono-
ruthenated – are indeed formed where ruthenium fragments are coordinated to DNA nucleobases. 
The two cis isomers (2 and 4) turned out to be more reactive than the respective trans species (1 and 
3). Finally, the four Ru(II) compounds manifested rather moderate antiproliferative properties 
against the two investigated cell lines: HCT-116 (human colon cancer) and FLG 29.1 (human acute 
myeloid leukemia). Consistent with the results described above, the cis isomers 2 and 4 were found 
to be significantly more effective than the trans congeners 1 and 3 in the leukemia cell line FLG 
29.1. 
The only investigated Ru(III) complex, 5, deserves a separate comment. It was found to be very 
inert, both in pure water and in buffer, and basically unreactive towards the investigated 
biomolecules and devoid of any relevant cytotoxic activity towards the investigated cancer cell 
lines. Given the structural similarity between 5 and well known anticancer compounds KP-
1019/NKP-1339 and NAMI-A, these findings were particularly disappointing. Nevertheless, they 
might suggest that for this type of anionic Ru(III) complexes, cytotoxicity is strictly related to the 
activation kinetics. Whereas the lack of cytotoxic activity of NAMI-A has been attributed to the fast 
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kinetics that lead to aquated Ru(III) metabolites unable to cross the cell membrane [56-57], the 
scarce activity of 5 might be attributed to exceedingly slow kinetics and to the consequential 
paucity of reactive aqua species. The intermediate activation kinetics (i.e. chloride release) of the 
more cytotoxic KP-1019/NKP-1339 complexes are apparently in the optimal range for observing in 
vitro activity. 
 
Keywords: Ruthenium complexes; PTA; protein interaction; oligonucleotide interaction; in vitro 
antriproliferative activity 
 
Highlights: 
• Water-soluble Ru(II/III)-halide-PTA complexes (PTA =  1,3,5-triaza-7-phosphaadamantane) 
• Structure and pH dependent solution behavior of the Ru(II)-PTA complexes. 
• Evident interaction of such complexes with a single strand reference oligonucleotide 
• Modest reactivity of the ruthenium compounds towards model proteins 
• Structure dependent antiproliferative properties of the five ruthenium compounds
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ESI-MS Electrospray ionization mass spectrometry 
KP-1019 [indH]trans-[RuCl4(ind)2], ind = indazole 
NAMI-A [imH]trans-[RuCl4(dmso-S)(im)], im = imidazole  
NKP-1339 [Na]trans-[RuCl4(ind)2], ind = indazole 
ODN  Oligodeoxyribonucleotide 
PTA  1,3,5-triaza-7-phosphaadamantane 
PTAH  PTA protonated at one N atom 
RAPTA Ruthenium-arene-PTA 
RNase A Ribonuclease A 
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Synopsis 
This work reports the preparation and characterization of five water-soluble Ru(II)- and Ru(III)-
halide-PTA (PTA = 1,3,5-triaza-7-phosphaadamantane) complexes. The structure and pH 
dependent solution behavior of the compounds, their interactions with model proteins and with a 
single strand reference oligonucleotide, and their antiproliferative properties are discussed in 
comparison with established ruthenium drug candidates in clinical development. 
